Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-12-21

FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application from Prasco Laboratories for a Pioglitazone and Glimepiride product. This adds a fixed-dose combination treatment for ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pioglitazone and Glimepiride (pioglitazone and glimepiride)

Snippet

SUPPL AP for PIOGLITAZONE AND GLIMEPIRIDE (PIOGLITAZONE AND GLIMEPIRIDE)